{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:07:10Z","timestamp":1790816830645,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2120260515565"],"award-info":[{"award-number":["2120260515565"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002562","name":"Sunchon National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002562","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.taap.2026.118016","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:55:03Z","timestamp":1787673303000},"page":"118016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Physiologically based pharmacokinetic modeling of propofol: Impact of liver cirrhosis on systemic exposure and model-informed dose optimization according to Child\u2013Pugh classification"],"prefix":"10.1016","volume":"516","author":[{"given":"Hee-Yeong","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hun","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hyun","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.taap.2026.118016_bb0005","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bcp.15990","article-title":"Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: impact on pharmacokinetics and drug\u2013drug interactions","volume":"90","author":"Armani","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.taap.2026.118016_bb0010","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2165\/00003495-199550030-00008","article-title":"Propofol","volume":"50","author":"Bryson","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.taap.2026.118016_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.809393","article-title":"Clinical importance of potential genetic determinants affecting propofol pharmacokinetics and pharmacodynamics","volume":"9","author":"Budic","year":"2022","journal-title":"Front. Med."},{"issue":"6","key":"10.1016\/j.taap.2026.118016_bb0020","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/oxfordjournals.bja.a013592","article-title":"Effects of propofol on functional activities of hepatic and extrahepatic conjugation enzyme systems","volume":"84","author":"Chen","year":"2000","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.taap.2026.118016_bb0025","doi-asserted-by":"crossref","first-page":"6925","DOI":"10.12659\/MSM.910103","article-title":"Pharmacokinetic analysis of propofol target-controlled infusion models in Chinese patients with hepatic insufficiency","volume":"24","author":"Chi","year":"2018","journal-title":"Med. Sci. Monit."},{"issue":"1","key":"10.1016\/j.taap.2026.118016_bb0030","article-title":"Metabolic profiles of propofol and fospropofol: clinical and forensic interpretative aspects","volume":"2018","author":"Dinis-Oliveira","year":"2018","journal-title":"Biomed. Res. Int."},{"issue":"11","key":"10.1016\/j.taap.2026.118016_bb0035","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00003088-200847110-00005","article-title":"Physiology-based simulations of a pathological condition","volume":"47","author":"Edginton","year":"2008","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.taap.2026.118016_bb0040","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1213\/ANE.0000000000000165","article-title":"A general purpose pharmacokinetic model for propofol","volume":"118","author":"Eleveld","year":"2014","journal-title":"Anesth. Analg."},{"issue":"9","key":"10.1016\/j.taap.2026.118016_bb0045","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1021\/acs.molpharmaceut.1c00462","article-title":"Non-uniformity of changes in drug-metabolizing enzymes and transporters in liver cirrhosis: implications for drug dosage adjustment","volume":"18","author":"El-Khateeb","year":"2021","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.taap.2026.118016_bb0050","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.bja.2025.05.036","article-title":"Impact of genetic variations on the pharmacokinetics, dose requirements, and clinical effects of propofol: a systematic review","volume":"135","author":"Gerstman","year":"2025","journal-title":"Br. J. Anaesth."},{"issue":"4","key":"10.1016\/j.taap.2026.118016_bb0055","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1124\/dmd.112.050294","article-title":"Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data","volume":"41","author":"Gill","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.taap.2026.118016_bb0060","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.clpt.2003.12.004","article-title":"Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding","volume":"75","author":"Hiraoka","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.taap.2026.118016_bb0065","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1208\/s12249-024-02995-4","article-title":"Pharmacokinetic prediction of immediate- and extended-release tablets for patients with liver disease using whole body physiologically-based pharmacokinetic modeling for the antipsychotic drug quetiapine","volume":"26","author":"Jang","year":"2024","journal-title":"AAPS PharmSciTech"},{"issue":"11","key":"10.1016\/j.taap.2026.118016_bb0070","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1016\/j.xphs.2022.08.035","article-title":"Physiologically based pharmacokinetic (PBPK) modeling of lornoxicam: exploration of doses for CYP2C9 genotypes and patients with cirrhosis","volume":"111","author":"Jeong","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.taap.2026.118016_bb0075","doi-asserted-by":"crossref","DOI":"10.1007\/s00210-026-05191-2","article-title":"Physiologically based pharmacokinetic modeling of immediate-release and extended-release formulations of doxazosin, an alpha-1 adrenergic receptor antagonist, with model simulations for patients with liver disease","author":"Jeong","year":"2026","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"3","key":"10.1016\/j.taap.2026.118016_bb0080","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11318160-000000000-00000","article-title":"A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance","volume":"49","author":"Johnson","year":"2010","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.taap.2026.118016_bb0085","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s00540-018-2470-3","article-title":"Impact of clinical factors and UGT1A9 and CYP2B6 genotype on inter-individual differences in propofol pharmacokinetics","volume":"32","author":"Kanaya","year":"2018","journal-title":"J. Anesth."},{"issue":"4","key":"10.1016\/j.taap.2026.118016_bb0090","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2165\/00003495-198835040-00002","article-title":"Propofol","volume":"35","author":"Langley","year":"1988","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.taap.2026.118016_bb0095","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/jcph.70079","article-title":"Precision pharmacokinetics of quetiapine: a physiologically based model incorporating liver cirrhosis and CYP3A4 polymorphisms","volume":"65","author":"Lee","year":"2025","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.taap.2026.118016_bb0100","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2253-5-4","article-title":"Human physiologically based pharmacokinetic model for propofol","volume":"5","author":"Levitt","year":"2005","journal-title":"BMC Anesthesiol."},{"key":"10.1016\/j.taap.2026.118016_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2015.12.017","article-title":"Adverse drug reactions and organ damage: the liver","volume":"28","author":"Licata","year":"2016","journal-title":"Eur. J. Intern. Med."},{"issue":"1","key":"10.1016\/j.taap.2026.118016_bb0110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/bja\/67.1.41","article-title":"Pharmacokinetic model driven infusion of propofol in children","volume":"67","author":"Marsh","year":"1991","journal-title":"Br. J. Anaesth."},{"issue":"4","key":"10.1016\/j.taap.2026.118016_bb0115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00023210-200317040-00003","article-title":"Propofol","volume":"17","author":"McKeage","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.taap.2026.118016_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.972793","article-title":"Effects of different anesthetic depth during propofol anesthesia on postoperative recovery 24 h after arthroscopic day surgery: a randomized clinical trial","volume":"13","author":"Ning","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.taap.2026.118016_bb0125","series-title":"A Short Guide to Clinical Pharmacokinetics","first-page":"67","article-title":"Effect of renal and hepatic diseases on pharmacokinetics","author":"Peeriga","year":"2024"},{"key":"10.1016\/j.taap.2026.118016_bb0130","series-title":"Clinical Principles of Anesthetic Pharmacology","first-page":"121","author":"Robert","year":"2015"},{"issue":"12","key":"10.1016\/j.taap.2026.118016_bb0135","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s40262-018-0672-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of propofol","volume":"57","author":"Sahinovic","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.taap.2026.118016_bb0140","series-title":"Diseases of the Abdomen and Pelvis 2018\u20132021: Diagnostic Imaging - IDKD Book","first-page":"229","article-title":"Diffuse liver disease: cirrhosis, focal lesions in cirrhosis, and vascular liver disease","author":"Schawkat","year":"2018"},{"issue":"5","key":"10.1016\/j.taap.2026.118016_bb0145","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1097\/00000542-199805000-00006","article-title":"The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers","volume":"88","author":"Schnider","year":"1998","journal-title":"Anesthesiology"},{"issue":"6","key":"10.1016\/j.taap.2026.118016_bb0150","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00000542-198812000-00014","article-title":"Pharmacokinetics and protein binding of propofol in patients with cirrhosis","volume":"69","author":"Servin","year":"1988","journal-title":"Anesthesiology"},{"issue":"2","key":"10.1016\/j.taap.2026.118016_bb0155","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/bja\/65.2.177","article-title":"Pharmacokinetics of propofol infusions in patients with cirrhosis","volume":"65","author":"Servin","year":"1990","journal-title":"Br. J. Anaesth."},{"issue":"4","key":"10.1016\/j.taap.2026.118016_bb0160","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00000542-199304000-00008","article-title":"Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study","volume":"78","author":"Servin","year":"1993","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.taap.2026.118016_bb0165","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/187231207779814355","article-title":"Effects of propofol analogs on glucuronidation of propofol, an anesthetic drug, by human liver microsomes","volume":"1","author":"Shimizu","year":"2007","journal-title":"Drug Metab. Lett."},{"key":"10.1016\/j.taap.2026.118016_bb0170","series-title":"Modern Anesthetics","first-page":"227","article-title":"Propofol","author":"Vanlersberghe","year":"2008"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X26003121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X26003121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:46:53Z","timestamp":1790815613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X26003121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":34,"alternative-id":["S0041008X26003121"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2026.118016","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically based pharmacokinetic modeling of propofol: Impact of liver cirrhosis on systemic exposure and model-informed dose optimization according to Child\u2013Pugh classification","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2026.118016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118016"}}